Objectives: Myeloid-derived suppressor cells (MDSCs) have been described as suppressors of T-cell functions in many tumor models. However, MDSC in HIV-1 infection have not been studied to date. As impaired T-cell function is a hallmark of chronic progressive HIV-1 infection, we hypothesized that MDSC also play a role here.
Introduction
In the natural course of HIV infection, viremia is controlled by the majority of infected individuals for a certain time. However, loss of control occurs at some point in the majority of individuals [1] . HIV-specific CD8 T cells are an important component of the adaptive immune response against HIV, yet these cells become ineffective in most chronically infected individuals [2, 3] . The reasons for this change in effectiveness are not completely understood so far.
Myeloid-derived suppressor cells (MDSCs) accumulate in various malignant diseases and were shown to exert suppressive regulatory functions especially on T cells [4] [5] [6] . In the mouse model, MDSCs are defined by the expression of the markers CD11b and Gr1 [5] . Lacking the marker Gr1, MDSCs in humans are less well defined. There are mainly two different phenotypes that have been described in cancer patients: CD11b þ CD14 À CD33 þ CD15 þ [7, 8] and CD14 þ HLA-DR À/low [9, 10] .
We hypothesized that MDSC also contribute to T-cell dysfunction in chronic progressive HIV infection, analogous to what is seen in cancer. We, therefore, assessed MDSC frequencies in HIV-infected individuals of various disease stages in comparison to healthy controls. Additionally, we examined MDSC function of HIV-infected individuals in vitro.
Methods

Study participants
Ninety-seven individuals participated in the study after signing informed consent. The study was approved by the Institutional Review Board of the Ludwig-Maximilians-Universität, Munich. The study participants were divided into the following groups (supplementary digital content S1, http://links.lww.com/QAD/A218): 16 healthy controls; 20 HIV-infected individuals on HAART with undetectable viral load (<50 copies/ml) for at least 2 years; 49 HIV-infected HAART-naive individuals [CD4 cell counts: 422 cells/ml, range 16-1237; viral load: 11 532 copies/ml, range 59-570 156 copies/ml; two individuals were hepatitis C virus (HCV) coinfected], four HIV-infected individuals with a failing salvage HAART without further treatment options and eight individuals with advanced nonsmall cell lung carcinoma (NSCLC) as positive controls. Seven of the 49 HAARTnaive individuals were reassessed at least 6 weeks after starting HAART. HIV-infected individuals with proven or suspected malignancy based on clinical, biochemical or radiological findings were excluded from the study.
Cell isolation and separation
Peripheral blood mononuclear cells (PBMC) were isolated from freshly obtained blood by Ficoll density gradient centrifugation. For isolation of CD11b þ CD14 À MDSC, PBMC were purified by a negative selection of CD14 þ cells followed by a positive selection of CD11b þ cells using magnetic microbeads (Stemcell Technologies, France) according to manufacturer's instructions. Purity for bead-isolated CD11b þ CD14 À CD33 þ CD15 þ MDSC was 60-96%. MDSC-depleted PBMC contained 0.7-4.0% MDSC.
Flow cytometry analysis
Extracellular staining with fluorescent antibodies was performed as described previously [11] . The following antibodies were used: CD14-APC, CD11b-FITC, CD33-PE, CD15-PerCP, HLA-DR-PerCP, CD38-PE, CD25-FITC, CD8-PerCP, CD4-APC (Biolegend, Aachen, Germany), CD38-PE (BD, Heidelberg, Germany), IL4Ralpha-PE and isotype control (R&DSystems, Wiesbaden, Germany). Intracellular staining with anti-FoxP3-PE (Biolegend) was performed using the FoxP3 staining buffer set (eBiosciences, Frankfurt, Germany) (as described [12] ). Cells were collected on a FACSCalibur (BD). Data was analyzed using FlowJo software (TriStar, Ashland, Oregon, USA). For gating strategies, see supplementary digital content S2, http:// links.lww.com/QAD/A218. As monocyte frequencies vary widely in individuals with a chronic viral infection, we expressed MDSC as percentage of PBMC.
Mixed lymphocyte reaction and proliferation assays
Allogeneic PBMC from healthy controls or from HIV controllers were labeled with carboxyfluorescein succinimidyl ester as described [13] . They were then stimulated with phytohemagglutinine (PHA) (1.25 mg/ml; healthy controls) or a pool of Gag/Nef overlapping peptides (100 mg/ml; HIV controllers) and incubated alone, with bead-isolated MDSC or with study participants' PBMC depleted of MDSC (ratio ¼ 2 : 1) in RPMI media with 10% fetal calf serum (PAA, Cölbe, Germany). After 72-96 h, cells were stained for CD8-PerCP (Biolegend) and analyzed. For analysis of regulatory T-cell (Treg) frequencies, cells were stained for CD4, CD25 and FoxP3 after coincubation.
Statistical analysis
GraphPad Prism Version 5 (Graph Pad Software, La Jolla, California, USA) was used to analyze data. Mann-Whitney tests were used to compare groups and linear regression analysis for correlations. Paired Student's t-test was used for paired comparisons. A P-value less than 0.05 was considered statistically significant. HIV-infected individuals to those in healthy controls and to individuals with advanced NSCLC. We found that HIV-infected HAART-naive individuals had significantly higher CD11b þ CD14 À CD33 þ CD15 þ MDSC frequencies than healthy controls (P ¼ 0.01; Fig. 1a ).
Results
We next assessed whether there was an association of MDSC levels with different stages of HIV infection. As MDSC levels of HAART-naive progressors and individuals with failure of salvage regimen were comparable ( Fig. 1d) , we combined the two groups for this analysis. Controllers (defined as viral load <5000 copies/ml; HAART-naive) on average had significantly lower MDSC frequencies than individuals with progressive disease (defined as viral load >50 000 copies/ml; P ¼ 0.0004; Fig. 1b ). Likewise, individuals with a CD4 cell count more than 500 cells/ml (HAART-naive) had significantly less MDSC than individuals with a CD4 cell count less than 250 cells/ml ( Fig. 1b ; P ¼ 0.0001). MDSC levels of individuals with medium viral load (5000-50 000 copies/ml) and medium CD4 cell count (250-500 cells/ml) were not significantly different from those of controllers ( Fig. 1b ). When looking at all participants, however, there was a statistically significant positive correlation of MDSC frequencies with viral load ( Fig. 1c ; r 2 ¼ 0.24, P ¼ 0.0002) and a negative correlation with CD4 cell count ( Fig. 1c ; r 2 ¼ 0.29, P < 0.0001). In addition MDSC levels correlated significantly with immune activation, measured as CD38 expression, on bulk CD8 T cells (r 2 ¼ 0.23, P ¼ 0.02; data not shown) and on HIV-specific CD8 T cells (r 2 ¼ 0.35, P ¼ 0.002; Fig. 1e ).
We then asked the question whether effective HAART affects the MDSC level. We found lower frequencies of MDSC in individuals on HAARTwith undetectable viral load for at least 2 years compared to HAART-naive individuals with viral load more than 5000 copies/ml ( Fig. 1d ; P ¼ 0.004). Seven of the HAART-naive individuals could be studied again after initiation of HAART. This analysis showed that HAART led to a rapid drop of MDSC levels ( Fig. 1d ; P ¼ 0.003). There was no difference in MDSC levels between individuals on effective HAART and spontaneous controllers (defined as viral load less than 5000 copies/ml; HAART-naive; P ¼ 0.58; Fig. 1d ).
Taken together, we found that CD11b þ CD14 À CD33 þ CD15 þ MDSC are associated with high viral loads and poor CD4 status in chronic HIV infection.
Another potential phenotype of human MDSC is CD14 þ HLA-DR À/low . Such cells (CD11b þ CD14 þ HLA-DR low CD33 þ ) have recently been described in individuals with chronic HCV infection [14] . We examined levels of CD11b þ CD14 þ HLA-DR À/low MDSC in a subgroup of the HAART-naive group and in the group on effective HAART. We did not find a positive correlation with viral load in the HAART-naive subgroup (r 2 ¼ 0.0004, P ¼ 0.95; data not shown).
Neither was there a statistically significant difference between HAART-naive individuals and individuals on HAART (P ¼ 0.64; data not shown).
CD11b R CD14 S CD33 R CD15 R myeloid-derived suppressor cells in HIV-infected individuals express IL4Ralpha and impair the proliferative capacity of CD8 T cells of healthy donors and HIV controllers Tumor-derived MDSC with suppressor function have been described to express IL4Ralpha [15] . CD11b þ CD14 À CD33 þ CD15 þ MDSC of our cohorts also expressed IL4Ralpha suggesting suppressor activity (supplementary digital content S3, http://links.lww. com/QAD/A218).
To further characterize MDSC function in progressive HIV-infection, we tested for their suppressive activity on intact CD8 T cells directly ex vivo. Bead-isolated MDSC of six different HIV-infected progressors led to significantly reduced proliferation of PHA-stimulated CD8 T cells of healthy donors (P ¼ 0.004; Fig. 2b ) and Gag/Nefpeptide stimulated CD8 T cells of HIV controllers (P ¼ 0.004; Fig. 2c ) in coculture experiments compared to incubation with progressors' MDSC-depleted PBMC. The latter did not significantly alter proliferation compared to the controls wherein no cells of HIVinfected individuals were added.
MDSC levels correlated highly significantly with the frequency of CD4 þ CD25 þ FoxP3 þ Tregs in a subgroup of the 49 HAART-naive individuals (r 2 ¼ 0.54, P < 0.0001; Fig. 2d ) directly ex vivo. This correlation was even stronger than the correlation between Treg levels and viral load (r 2 ¼ 0.31, P ¼ 0.006; data not shown). Hence, we assessed Tregs in coincubation experiments. Incubation of PBMC of HIV controllers with MDSC of progressors led to significantly increased Treg frequencies compared to incubation of those cells with MDSCdepleted PBMC of progressors (P ¼ 0.0008; Fig. 2e ).
CD11b þ CD14 À CD33 þ CD15 þ MDSC of HIV-infected individuals are of suppressive function shown by the expression of IL4Ralpha and the reduction of proliferative capacity of bulk and HIV-specific CD8 T cells. Induction of Treg frequencies is, therefore, proposed to be one mechanism by which MDSC exert their suppressive function.
Discussion
MDSC have been described in various malignant diseases and sepsis as inhibitory regulators of T cells [6, 16] . Here we show for the first time that CD11b þ CD14 À CD33 þ CD15 þ MDSC can be found to be elevated in progressive Comparison between low (<5000 copies/ml), medium (5000-50 000 copies/ml) and high (>50 000 copies/ml) viral load (VL) of HAART-naive individuals and individuals with failing salvage regimen (P ¼ 0.0004 and P ¼ 0.0003 respectively; Mann-Whitney Test). Right: Comparison between high (>500 cells/ml), medium (250-500 cells/ml) and low (<250 cells/ml) CD4 cell counts (P ¼ 0.0001 and P < 0.0001 respectively; Mann-Whitney-Test). HIV infection and also prove their suppressive function on CD8 T lymphocytes.
As comparison we used individuals with advanced NSCLC. NSCLC and renal cell carcinoma are those malignancies wherein CD11b þ CD14 À CD33 þ CD15 þ MDSC have been characterized in most detail [7, 8] .
The median level of MDSC in NSCLC was higher than in untreated HIV infection not selected for disease status.
Comparing NSCLC patients with HIV-infected progressors with very advanced disease status, the difference becomes less apparent. Disease status seems to be an important factor for the existence of MDSC. This is also reflected in the correlation of MDSC levels with well defined clinical markers of HIV infection, viral load and CD4 cell count.
Initiation of HAART resulted in a prompt reduction of MDSC frequencies. In addition, individuals on effective HAART had MDSC levels comparable to HIV controllers and healthy controls. Therefore, HIV viremia seems to be a direct inducer of MDSC. This and other possible mechanisms by which these cells are induced should be the goal of future studies.
Recently it has been shown that hepatitis C virus is an inducer of MDSC with a different phenotype [14] . We were not able to find differences between various disease stages in HIV infection for this phenotype. However, in the report by Tacke et al. [14] , PBMC of only five individuals with HCV infection were studied directly ex vivo, as we did with our participants. Clinical data, for example viral load, for these individuals were not mentioned. A more detailed analysis with the same method is necessary to finally compare the two findings.
When testing for the suppressive capacity of MDSC, proliferation of the target cell is often used as read out. Loss of proliferative capacity of T cells has been described as an effect of human MDSC in hepatocellular carcinoma [10] and renal cell carcinoma [8] and of murine MDSC in mouse tumor models [17] . In addition, the expression of IL4Ralpha has been associated with suppressive function of MDSC in mice [18] and humans [15] . Therefore, we assume that the MDSC population isolated from HIV progressors is of suppressive function. As one mechanism by which MDSC exert their suppressive function, the induction of Tregs has been proposed [10] . We confirmed this for HIV-derived MDSC in coincubation experiments. The relevance of this finding is also stressed by the observation that the correlation between Tregs and MDSC was stronger than the correlation between Tregs and viral load. Nevertheless, we expect additional mechanisms of action to be used by MDSC in HIV infection, which should be assessed in future studies.
In summary, this is the first report of an association of elevated CD11b þ CD14 À CD33 þ CD15 þ MDSC levels with chronic progressive HIV-1 infection. As impaired CD8 T-cell function is a hallmark of progressive HIV infection, reducing MDSC production or function could potentially become an adjunct therapeutic approach in this disease stage.
